A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas

Radiation Oncology (Impact Factor: 2.55). 01/2014; 9(1):38. DOI: 10.1186/1748-717X-9-38
Source: PubMed


While most meningiomas are benign, aggressive meningiomas are associated with high levels of recurrence and mortality. A single institution's Gamma Knife radiosurgical experience with atypical and malignant meningiomas is presented, stratified by the most recent WHO classification.
Thirty-one patients with atypical and 4 patients with malignant meningiomas treated with Gamma Knife radiosurgery between July 2000 and July 2011 were retrospectively reviewed. All patients underwent prior surgical resection. Overall survival was the primary endpoint and rate of disease recurrence in the brain was a secondary endpoint. Patients who had previous radiotherapy or prior surgical resection were included. Kaplan-Meier and Cox proportional hazards models were used to estimate survival and identify factors predictive of recurrence and survival.
Post-Gamma Knife recurrence was identified in 11 patients (31.4%) with a median overall survival of 36 months and progression-free survival of 25.8 months. Nine patients (25.7%) had died. Three-year overall survival (OS) and progression-free survival (PFS) rates were 78.0% and 65.0%, respectively. WHO grade II 3-year OS and PFS were 83.4% and 70.1%, while WHO grade III 3-year OS and PFS were 33.3% and 0%. Recurrence rate was significantly higher in patients with a prior history of benign meningioma, nuclear atypia, high mitotic rate, spontaneous necrosis, and WHO grade III diagnosis on univariate analysis; only WHO grade III diagnosis was significant on multivariate analysis. Overall survival was adversely affected in patients with WHO grade III diagnosis, prior history of benign meningioma, prior fractionated radiotherapy, larger tumor volume, and higher isocenter number on univariate analysis; WHO grade III diagnosis and larger treated tumor volume were significant on multivariate analysis.
Atypical and anaplastic meningiomas remain difficult tumors to treat. WHO grade III diagnosis and treated tumor volume were significantly predictive of recurrence and survival on multivariate analysis in aggressive meningioma patients treated with radiosurgery. Larger tumor size predicts poor survival, while nuclear atypia, necrosis, and increased mitotic rate are risk factors for recurrence. Clinical and pathologic predictors may help identify patients that are at higher risk for recurrence.

Download full-text


Available from: Joseph Simpson, Apr 06, 2015
16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atypical meningiomas (AM) frequently recur following gross total resection (GTR). We conducted a meta-analysis to evaluate the benefit of adjuvant therapy after GTR of AMs. A PubMed/MEDLINE search identified studies detailing AMs treated by GTR alone or GTR and adjuvant RT, published between 1984-2012. Original data from 14 retrospective studies were combined and analyzed. Odds ratio (OR) and chi-square testing were used when appropriate. Selected data sets were used to generate each variable, where available. 757 patients (M to F ratio 9:10) with AMs were included, 72.52%(n=549) of atypical meningiomas were treated by GTR alone and 27.47%(n=208) underwent adjuvant RT after GTR to a median dose of 54 Gy. The crude recurrence rate was twice as high without adjuvant RT(33.7% vs. 15%, P = 0.005). The 1-year local control (LC) rate was 90% for GTR and 97% for GTR + RT(OR=3.36, P=0.11). The median 5-year LC rate was 62% for GTR and 73% for GTR + RT respectively, (OR=1.71, P=0.06). The 5-yr overall survival for each group was 90% (OR=0.97, P=0.95). 85% of recurrences that were salvaged, 33% by RT and 67% required surgery. Radiation-related toxicity was <10%, at a median follow-up of 42 months. Postoperative RT for AMs may decrease risk for disease relapse and improve local control, although most tumors are salvageable with surgery or radiation. While the data suggests little or no impact of postoperative RT on survival, further investigation regarding the long term efficacy and toxicity of radiation is warranted. Copyright © 2014 Elsevier Inc. All rights reserved.
    World Neurosurgery 12/2014; 83(5). DOI:10.1016/j.wneu.2014.12.037 · 2.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The management of WHO Grade II "atypical" meningiomas (AMs) and Grade III "malignant" meningiomas (MMs) remains controversial and under-investigated in prospective studies. The roles of surgery, radiation therapy, radiosurgery, and chemotherapy have been incompletely delineated. This has left physicians to decipher how they should treat patients on a case-by-case basis. In this study, the authors review the English-language literature on the management and clinical outcomes associated with AMs and MMs diagnosed using the WHO 2000/2007 grading criteria. Twenty-two studies for AMs and 7 studies for MMs were examined in detail. The authors examined clinical decision points using the literature and concepts from evidence-based medicine. Acknowledging the retrospective nature of the studies concerning AM and MM, the authors did find evidence for the following clinical strategies: 1) maximal safe resection of AM and MM; 2) active surveillance after gross-total resection of AM; 3) adjuvant radiation therapy after subtotal resection of AM, especially in the absence of putative radioresistant features; and 4) adjuvant radiation therapy after resection of MM.
    Neurosurgical FOCUS 03/2015; 38(3):E3. DOI:10.3171/2015.1.FOCUS14757 · 2.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although meningioma stem-like cells have been isolated and characterized, their therapeutic targeting remains a challenge. Meningioma sphere cells (MgSCs) with cancer stem cells properties show chemo- and radioresistance in comparison with meningioma adherent cells (MgACs). We tested the effect of valproic acid (VPA), a commonly used anti-epileptic drug, which passes the blood brain barrier, on cultured MgSCs. VPA reduced the viability of MgSCs and MgACs. In MgSCs, treatment with VPA increased radio-sensitivity, expression of p-cdc2, p-H2AX and cleaved caspase-3 and PARP. Anchorage-independent growth (AIG) was reduced by VPA. AIG was further reduced by combined treatment with irradiation. Expression of a stem cell marker, Oct4, was reduced by VPA. Oct4 was further decreased by combined treatment with irradiation. These results suggest that VPA may be a potential treatment for meningioma through targeting meningioma stem-like cells.
    Oncotarget 03/2015; 6(12). DOI:10.18632/oncotarget.3692 · 6.36 Impact Factor
Show more